Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q3 2023 · 10-Q
Revenue$180.00K$180.00K−49.7% vs Q3 2022 Net Income-$9.76M-$9.76MN/M vs Q3 2022 EPS, diluted—
Operating Income-$9,766,500N/M Operating Cash Flowderived-$9,933,300N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
Free Cash Flowderived-$9,945,800N/M Margins · derivedOperating margin-5425.8%−2480.8 pt vs Q3 2022
Net margin-5422.9%−2479.3 pt vs Q3 2022
ended Dec 31, 2022 · filed Feb 7, 2023 · 38 d after period end